Production & Manufacturing

ADIENNE Pharma signs manufacturing deal with Selexis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Business & Industry

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.
Business & Industry

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.
Business & Industry

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
- Advertisement -

ADIENNE Pharma & Biotech has signed a service agreement with Selexis for the development of a manufacturing cell line for one of the ADIENNE’s orphan drugs.

Selexis CEO Igor Fisch said, “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic.”

ADIENNE Pharma & Biotech founder and CEO Antonio Francesco Di Naro said Selexis expertise will be an added value for the company’s molecule.

Selexis is a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Latest stories

Previous article
Indian state plans non-generic drugs procurement for government hospitals
Next article
Clarity Pharmaceuticals, Dalton Pharma sign manufacturing services contract

Related stories

Business & Industry

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.
Business & Industry

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.
Business & Industry

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
Business & Industry

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Pharma navigating EPR split tier reality 2026

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing...

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring Regulatory Compliance in Pharmaceutical QC Labs